Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved capecitabine for reimbursement as a treatment option for the adjuvant treatment of stage I to IIIB triple negative breast cancer (TNBC) in patients with residual invasive disease after neoadjuvant chemotherapy treatment.
This is written in the approval document as:
Adjuvant treatment of stage I to IIIB, triple negative breast cancer (TNBC) in patients with residual invasive disease after neoadjuvant chemotherapy treatment.
Citation
Capecitabine Monotherapy, 2023, version number 7, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/216.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER negative, HER2-negative, PR negative | Invasive Breast Carcinoma | Capecitabine |